OBJECTIVES: Cardiac atrial appendage stem cells (CASCs) have recently emerged as an attractive candidate for cardiac regeneration after myocardial infarction. As with other cardiac stem cells, CASCs have to be expanded ex vivo to obtain clinically relevant cell numbers. However, foetal calf serum (FCS), which is routinely used for cell culturing, is unsuitable for clinical purposes, and influence of long-term in vitro culture on CASC behaviour is unknown. MATERIALS AND METHODS: We examined effects on CASC biology of prolonged expansion, and evaluated a culture protocol suitable for human use. RESULTS: In FCS-supplemented medium, CASCs could be kept in culture for 55.75 ± 3.63 days, before reaching senescence. Despite a small reduction in numbers of proliferating CASCs (1.37 ± 0.52% per passage) and signs of progressive telomere shortening (0.04 ± 0.02 kb per passage), their immunophenotype and myocardial differentiation potential remained unaffected during the entire culture period. The cells were successfully expanded in human platelet plasma supernatant, while maintaining their biological properties. CONCLUSIONS: We successfully developed a protocol for long-term culture, to obtain clinically relevant CASC numbers, while retaining their cardiogenic potential. These insights in CASC biology and optimization of a humanized platelet-based culture method are an important step towards clinical application of CASCs for cardiac regenerative medicine.
OBJECTIVES: Cardiac atrial appendage stem cells (CASCs) have recently emerged as an attractive candidate for cardiac regeneration after myocardial infarction. As with other cardiac stem cells, CASCs have to be expanded ex vivo to obtain clinically relevant cell numbers. However, foetal calf serum (FCS), which is routinely used for cell culturing, is unsuitable for clinical purposes, and influence of long-term in vitro culture on CASC behaviour is unknown. MATERIALS AND METHODS: We examined effects on CASC biology of prolonged expansion, and evaluated a culture protocol suitable for human use. RESULTS: In FCS-supplemented medium, CASCs could be kept in culture for 55.75 ± 3.63 days, before reaching senescence. Despite a small reduction in numbers of proliferating CASCs (1.37 ± 0.52% per passage) and signs of progressive telomere shortening (0.04 ± 0.02 kb per passage), their immunophenotype and myocardial differentiation potential remained unaffected during the entire culture period. The cells were successfully expanded in human platelet plasma supernatant, while maintaining their biological properties. CONCLUSIONS: We successfully developed a protocol for long-term culture, to obtain clinically relevant CASC numbers, while retaining their cardiogenic potential. These insights in CASC biology and optimization of a humanized platelet-based culture method are an important step towards clinical application of CASCs for cardiac regenerative medicine.
Authors: Gillian I Bell; Heather C Broughton; Krysta D Levac; David A Allan; Anargyros Xenocostas; David A Hess Journal: Stem Cells Dev Date: 2011-10-21 Impact factor: 3.272
Authors: Peter V Johnston; Tetsuo Sasano; Kevin Mills; Robert Evers; Shuo-Tsan Lee; Rachel Ruckdeschel Smith; Albert C Lardo; Shenghan Lai; Charles Steenbergen; Gary Gerstenblith; Richard Lange; Eduardo Marbán Journal: Circulation Date: 2009-09-08 Impact factor: 29.690
Authors: Katharina Schallmoser; Christina Bartmann; Eva Rohde; Andreas Reinisch; Karl Kashofer; Elke Stadelmeyer; Camilla Drexler; Gerhard Lanzer; Werner Linkesch; Dirk Strunk Journal: Transfusion Date: 2007-08 Impact factor: 3.157
Authors: Claudia Bearzi; Marcello Rota; Toru Hosoda; Jochen Tillmanns; Angelo Nascimbene; Antonella De Angelis; Saori Yasuzawa-Amano; Irina Trofimova; Robert W Siggins; Nicole Lecapitaine; Stefano Cascapera; Antonio P Beltrami; David A D'Alessandro; Elias Zias; Federico Quaini; Konrad Urbanek; Robert E Michler; Roberto Bolli; Jan Kajstura; Annarosa Leri; Piero Anversa Journal: Proc Natl Acad Sci U S A Date: 2007-08-20 Impact factor: 11.205
Authors: David M Hoganson; Dane A Cooper; Kimberly N Rich; Breanna L Piekarski; Liqiong Gui; Joseph P Gaut; John E Mayer; Elena Aikawa; Laura E Niklason; Sitaram M Emani Journal: Ann Thorac Surg Date: 2018-03-03 Impact factor: 4.330
Authors: Alexandros Chatgilialoglu; Martina Rossi; Francesco Alviano; Paola Poggi; Chiara Zannini; Cosetta Marchionni; Francesca Ricci; Pier Luigi Tazzari; Valentina Taglioli; Philip C Calder; Laura Bonsi Journal: Stem Cell Res Ther Date: 2017-02-07 Impact factor: 6.832